|
1
|
Hou P, Bojdani E and Xing M: Induction of
thyroid gene expression and radioiodine uptake in thyroid cancer
cells by targeting major signaling pathways. J Clin Endocrinol
Metab. 95:820–828. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ron E and Schneider AB: Thyroid
CancerCancer Epidemiology and Prevention. Schottenfeld D and
Fraumeni JF: Oxford University Press; New York: 2006, View Article : Google Scholar
|
|
3
|
Rahbari R, Zhang L and Kebebew E: Thyroid
cancer gender disparity. Future Oncol. 6:1771–1779. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aschebrook-Kilfoy B, Ward MH, Sabra MM and
Devesa SS: Thyroid cancer incidence patterns in the United States
by histologic type, 1992–2006. Thyroid. 21:125–134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schneider DF and Chen H: New developments
in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin.
63:374–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghossein R and Livolsi VA: Papillary
thyroid carcinoma tall cell variant. Thyroid. 18:1179–1181. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Livolsi VA, Albores-Saavedra J, Asa SL,
Baloch ZW, Sobrinho-Simoes M, Wenig B, DeLellis RA, Cady B,
Mazzaferri EL, Hay I, et al: Papillary CarcinomaPathology and
Genetics: Tumours of Endocrine Organs. World Health Organization
Classification of Tumours. DeLellis RA, Lloyd RV, Heitz R and Eng
C: IARC Press; Lyon: 2004
|
|
8
|
Kim KB, Cabanillas ME, Lazar AJ, Williams
MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical
responses to vemurafenib in patients with metastatic papillary
thyroid cancer harboring BRAF (V600E) mutation. Thyroid.
23:1277–1283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joo JY, Park JY, Yoon YH, Choi B, Kim JM,
Jo YS, Shong M and Koo BS: Prediction of occult central lymph node
metastasis in papillary thyroid carcinoma by preoperative BRAF
analysis using fine-needle aspiration biopsy: A prospective study.
J Clin Endocrinol Metab. 97:3996–4003. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kurtulmus N, Duren M, Ince U, Cengiz
Yakicier M, Peker O, Aydin O, Altiok E, Giray S and Azizlerli H:
BRAF (V600E) mutation in Turkish patients with papillary thyroid
cancer: Strong correlation with indicators of tumor aggressiveness.
Endocrine. 42:404–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aksamitiene E, Kiyatkin A and Kholodenko
BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt
pathways: A fine balance. Biochem Soc Trans. 40:139–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xing M: Genetic alterations in the
phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nikiforov YE and Nikiforova MN: Molecular
genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol.
7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu Z, Gandhi M, Nikiforova MN, Fischer AH
and Nikiforov YE: Molecular profile and clinical-pathologic
features of the follicular mutation of papillary thyroid carcinoma.
An unusually high prevalence of ras mutations. Am J Clin Pathol.
120:71–77. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park JY, Kim WY, Hwang TS, Lee SS, Kim H,
Han HS, Lim SD, Kim WS, Yoo YB and Park KS: BRAF and RAS mutations
in follicular mutation of papillary thyroid carcinoma. Endocr
Pathol. 24:69–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rivera M, Ricarte-Filho J, Knauf J, Shaha
A, Tuttle M, Fagin JA and Ghossein RA: Molecular genotyping of
papillary thyroid carcinoma follicular mutation according to its
histological subtypes (encapsulated vs infiltrative) reveals
distinct BRAF and RAS mutation patterns. Mod Pathol. 23:1191–1200.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adeniran AJ, Zhu Z, Gandhi M, Steward DL,
Fidler JP, Giordano TJ, Biddinger PW and Nikiforov YE: Correlation
between genetic alterations and microscopic features, clinical
manifestations and prognostic characteristics of thyroid papillary
carcinomas. Am J Surg Pathol. 30:216–222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu RT, Hou CY, You HL, Huang CC,
Hock-Liew, Chou FF, Wang PW and Cheng JT: Selective occurrence of
ras mutations in benign and malignant thyroid follicular neoplasms
in Taiwan. Thyroid. 14:616–621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang J, Pang J, Watanabe T, Ng HK and
Ohgaki H: Whole genome amplification for array comparative genomic
hybridization using DNA extracted from formalin-fixed,
paraffin-embedded histological sections. J Mol Diagn. 11:109–116.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang J, Zhao YP, Li Q, Zhang JX, Wang Y
and Zhang B: Association of single nucleotide polymorphisms of NBS1
gene with genetic susceptibility to primary liver cancer in a
Chinese Han population. Prog Biochem Biophys. 39:678–686. 2012.
View Article : Google Scholar
|
|
21
|
Huang J, Grotzer MA, Watanabe T, Hewer E,
Pietsch T, Rutkowski S and Ohgaki H: Mutations in the Nijmegen
breakage syndrome gene in medulloblastomas. Clin Cancer Res.
14:4053–4058. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qing W, Fang WY, Ye L, Shen LY, Zhang XF,
Fei XC, Chen X, Wang WQ, Li XY, Xiao JC and Ning G: Density of
tumor-associated macrophages correlates with lymph node metastasis
in papillary thyroid carcinoma. Thyroid. 22:905–910. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lloyd RV, Buehler D and Khanafshar E:
Papillary thyroid carcinoma mutation. Head Neck Pathol. 5:51–56.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okayasu I, Fujiwara M, Hara Y, Tanaka Y
and Rose NR: Association of chronic lymphocytic thyroiditis and
thyroid papillary carcinoma. A study of surgical cases among
Japanese and white and African Americans. Cancer. 76:2312–2318.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hiromatsu Y, Satoh H and Amino N:
Hashimoto's thyroiditis: History and future outlook. Hormones
(Athens). 12:12–18. 2013.PubMed/NCBI
|
|
26
|
Long J, Wang Y, Li M, Tong WM, Jia JD and
Huang J: Correlation of TP53 mutations with HCV positivity in
hepatocarcinogenesis: Identification of a novel TP53 microindel in
hepatocellular carcinoma with HCV infection. Oncol Rep. 30:119–124.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang MD, Chen XF, Xu G, Wu QQ, Zhang JH,
Chen GF, Cai Y and Qi FZ: Genetic variation in the NBS1 gene is
associated with hepatic cancer risk in a Chinese population. DNA
Cell Biol. 31:678–682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
29
|
Soares P, Trovisco V, Rocha AS, Lima J,
Castro P, Preto A, Máximo V, Botelho T, Seruca R and
Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are
alternative events in the etiopathogenesis of PTC. Oncogene.
22:4578–4580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Frattini M, Ferrario C, Bressan P,
Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P,
Gariboldi M, Pilotti S, et al: Alternative mutations of BRAF, RET
and NTRK1 are associated with similar but distinct gene expression
patterns in papillary thyroid cancer. Oncogene. 23:7436–7440. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dockhorn-Dworniczak B, Caspari S, Schroder
S, Bocker W and Dworniczak B: Demonstration of activated oncogenes
of the ras family in human thyroid tumors using the polymerase
chain reaction. Verh Dtsch Ges Pathol. 74:415–418. 1990.PubMed/NCBI
|
|
32
|
Schulten HJ, Al-Maghrabi J, Al-Ghamdi K,
Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari
M and Al-Qahtani M: Mutational screening of RET, HRAS, KRAS, NRAS,
BRAF, AKT1 and CTNNB1 in medullary thyroid carcinoma. Anticancer
Res. 31:4179–4183. 2011.PubMed/NCBI
|
|
33
|
Rivera M, Ricarte-Filho J, Tuttle RM,
Ganly I, Shaha A, Knauf J, Fagin J and Ghossein R: Molecular,
morphologic and outcome analysis of thyroid carcinomas according to
degree of extrathyroid extension. Thyroid. 20:1085–1093. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fujita J, Yoshida O, Yuasa Y, Rhim JS,
Hatanaka M and Aaronson SA: Ha-ras oncogenes are activated by
somatic alterations in human urinary tract tumours. Nature.
309:464–466. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kreimer-Erlacher H, Seidl H, Back B, Kerl
H and Wolf P: High mutation frequency at Ha-ras exons 1–4 in
squamous cell carcinomas from PUVA-treated psoriasis patients.
Photochem Photobiol. 74:323–330. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sathyan KM, Nalinakumari KR, Abraham T and
Kannan S: Influence of single nucleotide polymorphisms in H-Ras and
cyclin D1 genes on oral cancer susceptibility. Oral Oncol.
42:607–613. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Johne A, Roots I and Brockmoller J: A
single nucleotide polymorphism in the human H-ras proto-oncogene
determines the risk of urinary bladder cancer. Cancer Epidemiol
Biomarkers Prev. 12:68–70. 2003.PubMed/NCBI
|
|
38
|
Zhang Y, Jin M, Liu B, Ma X, Yao K, Li Q
and Chen K: Association between H-RAS T81C genetic polymorphism and
gastrointestinal cancer risk: A population based case-control study
in China. BMC Cancer. 8:2562008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Castro P, Soares P, Gusmão L, Seruca R and
Sobrinho-Simoes M: H-RAS 81 polymorphism is significantly
associated with aneuploidy in follicular tumors of the thyroid.
Oncogene. 25:4620–4627. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Esapa CT, Johnson SJ, Kendall-Taylor P,
Lennard TW and Harris PE: Prevalence of Ras mutations in thyroid
neoplasia. Clin Endocrinol (Oxf). 50:529–535. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu Z, Gandhi M, Nikiforova MN, Fischer AH
and Nikiforov YE: Molecular profile and clinical-pathologic
features of the follicular variant of papillary thyroid carcinoma.
An unusually high prevalence of ras mutations. Am J Clin Pathol.
120:71–77. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Santarpia L, Myers JN, Sherman SI,
Trimarchi F, Clayman GL and El-Naggar AK: Genetic alterations in
the RAS/RAF/mitogen-activated protein kinase and
phosphatidylinositol 3-kinase/Akt signaling pathways in the
follicular variant of papillary thyroid carcinoma. Cancer.
116:2974–2983. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Khan MS, Pandith AA, Ul Hussain M, Iqbal
M, Khan NP, Wani KA, Masoodi SR and Mudassar S: Lack of mutational
events of RAS genes in sporadic thyroid cancer but high risk
associated with HRAS T81C single nucleotide polymorphism
(case-control study). Tumour Biol. 34:521–529. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bos JL: ras oncogenes in human cancer: A
review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
|
|
45
|
Bos JL: The ras gene family and human
carcinogenesis. Mutat Res. 195:255–271. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hashimoto-Gotoh T, Kikuno R, Takahashi M
and Honkawa H: Possible role of the first intron of c-H-ras in gene
expression: anti-cancer elements in oncogenes. Anticancer Res.
8:851–859. 1988.PubMed/NCBI
|
|
47
|
Vasko V, Saji M, Hardy E, Kruhlak M, Larin
A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, et
al: Akt activation and localisation correlate with tumour invasion
and oncogene expression in thyroid cancer. J Med Genet. 41:161–170.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Janku F, Lee JJ, Tsimberidou AM, Hong DS,
Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I and Kurzrock
R: PIK3CA mutations frequently coexist with RAS and BRAF mutations
in patients with advanced cancers. PLoS One. 6:e227692011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zou M, Baitei EY, Alzahrani AS, BinHumaid
FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS
RET/PTC, or BRAF mutations in advanced stage of papillary thyroid
carcinoma. Thyroid. 24:1256–1266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Oliveira C, Velho S, Moutinho C, Ferreira
A, Preto A, Domingo E, Capelinha AF, Duval A, Hamelin R, Machado
JC, et al: KRAS and BRAF oncogenic mutations in MSS colorectal
carcinoma progression. Oncogene. 26:158–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Suarez HG, du Villard JA, Severino M,
Caillou B, Schlumberger M, Tubiana M, Parmentier C and Monier R:
Presence of mutations in all three ras genes in human thyroid
tumors. Oncogene. 5:565–570. 1990.PubMed/NCBI
|
|
52
|
Pilotti S, Collini P, Mariani L, Placucci
M, Bongarzone I, Vigneri P, Cipriani S, Falcetta F, Miceli R,
Pierotti MA and Rilke F: Insular carcinoma: A distinct de novo
entity among follicular carcinomas of the thyroid gland. Am J Surg
Pathol. 21:1466–1473. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ganly I, Ricarte Filho J, Eng S, Ghossein
R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA and Chan
TA: Genomic dissection of Hurthle cell carcinoma reveals a unique
class of thyroid malignancy. J Clin Endocrinol Metab. 98:E962–E972.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
DeLellis RA, Lloyd RV and Heitz PU: World
Health Organization Classification of Tumors. Pathology and
Genetics: Tumors of Endocrine Organs. IARC Press; Lyon, France: pp.
69–72. 2004
|
